Table 2.
Results regarding data availability and completeness
| Data source | Pooled data from 15 European registries collecting information on patients with SpA | |||||
|---|---|---|---|---|---|---|
| Pooled data (n=33,948) | Before January 1, 2015 (n=16,207) | From January 1, 2015 (n=21,423) | axSpA (n=21,330) | PsA (n=12,618) | ||
| Variables | No of registries with available data | Data completeness, mean % (range)a | Data completeness, mean %a | |||
| Demography | ||||||
| Age | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
| Sex | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
| Weight | 14 | 67 (7–100) | 71% | 64% | 68% | 65% |
| Height | 14 | 64 (13–100) | 65% | 64% | 65% | 63% |
| Lifestyle | ||||||
| Smoking | 13 | 85 (15–100) | 82% | 88% | 85% | 84% |
| Alcohol consumptionb | 4 | 29 (7–76) | 21% | 44% | 26% | 32% |
| Disease duration and classification criteria | ||||||
| Disease duration (years) | 15 | 92 (53–100) | 96% | 88% | 93% | 90% |
| Symptom duration (years) | 9 | 75 (33–100) | 72% | 78% | 75% | 74% |
| ASAS criteria | 9 | 46 (5–100) | 47% | 46% | 63% | 16% |
| Modified New York criteria | 9 | 38 (5–100) | 40% | 35% | 49% | 17% |
| CASPAR criteria | 7 | 27 (6–100) | 29% | 26% | 15% | 48% |
| Clinical characteristics at baseline | ||||||
| Swollen joint count (28) | 14 | 60 (28–100) | 59% | 61% | 45% | 85% |
| Tender joint count (28) | 14 | 56 (28–100) | 53% | 59% | 38% | 85% |
| Swollen joint count (66) | 10 | 29 (5–74) | 20% | 37% | 16% | 50% |
| Tender joint count (68) | 10 | 31 (6–76) | 21% | 39% | 17% | 54% |
| Physician global | 13 | 71 (13–92) | 71% | 71% | 64% | 82% |
| Enthesitis (MASES) | 6 | 25 (6–70) | 20% | 29% | 29% | 16% |
| Dactylitis (yes/no) | 5 | 33 (10–97) | 40% | 28% | 26% | 46% |
| Skin (PASI binary) | 4 | 40 (1–92) | 53% | 31% | 35% | 49% |
| Nails (NAPSI binary) | 2 | 44 (27–83) | 44% | 44% | 23% | 92% |
| BASMI | 8 | 26 (3–100) | 24% | 27% | 39% | 7% |
| Biological or targeted synthetic DMARD treatment | ||||||
| Name of b/tsDMARD | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
| Treatment series number | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
| Treatment start date | 15 | 100 (100–100) | 100% | 100% | 100% | 100% |
| Treatment stop date | 15 | 53 (5–71) | 69% | 39% | 51% | 56% |
| Concomitant medication at baseline | ||||||
| Conventional synthetic (cs) DMARD | 14 | 71 (2–100) | 67% | 74% | 68% | 75% |
| Methotrexate | 14 | 66 (2–100) | 64% | 68% | 63% | 71% |
| Sulfasalazine | 14 | 63 (2–100) | 62% | 65% | 63% | 65% |
| Leflunomide | 14 | 62 (2–100) | 60% | 63% | 60% | 64% |
| Other csDMARDs | 13 | 65 (2–100) | 60% | 68% | 63% | 67% |
| Oral glucocorticoidsc | 11 | 86 (33–100) | - | 86% | 84% | 88% |
| NSAIDs | 8 | 56 (16–100) | 42% | 69% | 61% | 46% |
| Patient-reported outcomes at baseline | ||||||
| BASDAI | 15 | 63 (28–100) | 54% | 71% | 78% | 39% |
| BASFI | 11 | 59 (16–100) | 50% | 68% | 74% | 35% |
| HAQ | 12 | 68 (14–97) | 63% | 72% | 58% | 83% |
| Patient global | 14 | 82 (43–100) | 79% | 85% | 79% | 87% |
| Patient fatigue | 8 | 68 (23–90) | 57% | 79% | 71% | 64% |
| Patient pain | 13 | 77 (26–100) | 68% | 86% | 74% | 82% |
| Laboratory parameters at baseline | ||||||
| CRP | 15 | 85 (22–100) | 88% | 83% | 85% | 85% |
| ESR | 13 | 84 (46–100) | 85% | 82% | 83% | 85% |
| HLA-B27 | 14 | 67 (8–95) | 63% | 71% | 80% | 46% |
| Peripheral and extra-musculoskeletal manifestations of spondyloarthritis (ever/never) | ||||||
| Enthesitis | 5 | 78 (73–100) | 82% | 75% | 80% | 73% |
| Dactylitis | 6 | 80 (4–100) | 91% | 72% | 79% | 81% |
| Psoriasis | 12 | 56 (2–100) | 61% | 53% | 60% | 50% |
| Uveitis | 11 | 84 (4–100) | 87% | 82% | 83% | 86% |
| Inflammatory bowel disease | 11 | 57 (1–100) | 61% | 53% | 60% | 51% |
| Comorbidities (ever/never) | ||||||
| Cardiovascular | 13 | 65 (10–100) | 63% | 68% | 69% | 59% |
| Diabetes | 13 | 55 (7–100) | 53% | 57% | 54% | 57% |
| Kidney disease | 12 | 66 (3–100) | 65% | 67% | 69% | 60% |
Unless otherwise stated, we used secondary pseudonymized baseline data from initiation of the first biologic (b) or targeted synthetic (ts) disease-modifying anti-rheumatic drug (DMARD) treatment on patients with a clinical diagnosis of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), 18 years or older, followed in one of the participating registries since the start of their first b/tsDMARD between 2000 to 2021. Sweden has provided data on Secukinumab-treated patients only
ASAS Assessment of Spondyloarthritis International Society, CASPAR Classification Criteria for Psoriatic Arthritis, MASES Maastricht Ankylosing Spondylitis Enthesitis Index, PASI Psoriasis Area and Severity Index, NAPSI Nail Psoriasis Severity Index, BASMI Bath Ankylosing Spondylitis Metrology Index, NSAID non-steroidal anti-inflammatory drug, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HAQ Health Assessment Questionnaire, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, HLA-B27 Human Leukocyte Antigen subtypes B*2701-2759
aAmong registries with available data on the variable
bData based on patients who initiated a TNFi between January 1, 2009, and December 31, 2018
cData based on patients who initiated a new b/tsDMARD from January 1, 2015, and May 31, 2022